Posts tagged as:

PBE

Here is a look at the 25 best and 25 worst ETFs from the past trading week. Traders can use this list to find prospective candidates that have deviated too far from their longer-term trends, thereby serving as potential starting points for those looking to take on either short or long positions. [click to continue…]

{ Comments on this entry are closed }

This year may have started off on shaky footing as our nation tiptoed near the fiscal cliff, but when we look in the rear view mirror its undeniable that the bulls prevailed from the beginning through the finals trading days of 2013. While a number of asset classes posted dismal returns, namely precious metals and volatility, a number of others managed to post stellar gains, even topping the S&P 500′s impressive +28% return for the year [see The Worst Performing ETFs of 2013]. [click to continue…]

{ Comments on this entry are closed }

This year has shaped up to be quite kind to investors as major equity indexes are holding onto double-digit gains ahead of the anticipated Santa Claus rally. Much to the bears’ frustration, the U.S. economy has continued its slow and steady expansion while the Federal Reserve’s commitment to an accommodative monetary policy continues to resonate […]

{ Comments on this entry are closed }

For Wall Street, the technology sector has been one of the most rewarding–yet frustrating–industries to invest in, as this corner of the market goes through periods of rapid revolutions, booms, and busts. But for those willing to stomach the risk, technology investments are some of the most promising, as developments made by these companies can […]

{ Comments on this entry are closed }

While some American’s were elated with Obama’s re-election, Wall Street made it quite clear who it had voted for as markets took a sharp nosedive in a post-election sell off immediately following the President’s victory. To many investors, Obama’s re-election has placed looming concerns over the Fiscal Cliff to the forefront, as the automatic round of […]

{ Comments on this entry are closed }

When it comes to the world of exchange-traded products, there are virtually no limits as to how investors can choose to play nearly every corner of the market. From compelling quant-based methodologies to hyper-targeted sector funds, there is an ETF to fit essentially every investor’s investment objective. But for those looking to gain access to some of […]

{ Comments on this entry are closed }

ProShares, a leading provider of leveraged and inverse ETFs, announced the launch on Friday of the first ETFs with leveraged and inverse exposure to the biotechnology sector. The Ultra Nasdaq Biotechnology (BIB) will seek to provide 200% of the return on the NASDAQ Biotechnology Index for a single day. The UltraShort Nasdaq Biotechnology (BIS) will […]

{ Comments on this entry are closed }

As the array of ETF product offerings has expanded in recent years, the biotech space has seen significant activity. Currently, there are five biotech ETFs that have accumulated nearly $3.5 billion in aggregate assets. Each of these funds focuses on stocks in the biotechnology industry, and in many cases there is significant overlap between the […]

{ Comments on this entry are closed }

Which Biotech ETF Is Best For You?

by on February 9, 2010 | Updated April 29, 2013

As the ETF industry has grown by leaps and bounds in recent years, continued innovation has enabled investors to achieve more granular exposure than ever through exchange-traded products. Diversified ETFs targeting relatively narrow sectors of the domestic and global economy have multiplied, including funds targeting the airline, gaming, insurance, gold mining, timber, and food and […]

{ Comments on this entry are closed }

Healthcare reform has been in the news a lot lately, with constant finger-pointing, debate, and competing versions of comprehensive bills. Although the passage of comprehensive reform appears to be less certain that it was only weeks ago, it remains likely that major changes are coming before the end of the year. While many specifics are […]

{ Comments on this entry are closed }

Biotechnology ETFs enjoyed bug jumps at the beginning of this week, thanks primarily to a huge increase in the stock price of a key component of several funds. Human Genome Sciences Inc. (HGSI) has jumped more than 450% over the last week on news that its lupus drug Benlysta showed late-stage success in a clinical […]

{ Comments on this entry are closed }